We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Kromek Group Plc | LSE:KMK | London | Ordinary Share | GB00BD7V5D43 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.40 | 5.84% | 7.25 | 7.00 | 7.50 | 7.25 | 6.85 | 6.85 | 1,554,889 | 16:18:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Miscellaneous Metal Ores,nec | 17.31M | -6.1M | -0.0102 | -7.11 | 43.52M |
Date | Subject | Author | Discuss |
---|---|---|---|
29/3/2022 10:00 | 8days till another Kromek deadline passes with the traditional failure to acknowledge, explain or apologise. Previously I had thought no PLC company would behave in such a dishonourable manner. However, it’s seems standard modus operandi for Kromek | aqc888 | |
26/3/2022 07:27 | Share price actually went down last time an ‘upto’ contract was announced after previous ‘upto’ failures. 11days till another Kromek deadline passes with the traditional failure to acknowledge, explain or apologise. | aqc888 | |
25/3/2022 07:08 | Kromek has no credibility left and soon (June- Charlie Buckets prediction) will have no money left either. Question is; are there enough mugs out there to partake in another fundraising, after all the previous ones which have proved to be nonsense… Could be at the end of the road and insolvent this time next year… they need to accelerate plans to sell parts of business, without a sale it’s over, a fact any buyer will be keen to exploit | aqc888 | |
23/3/2022 19:21 | Sorry The science is evasive, which means only one thing. IMO GLA | simithy | |
23/3/2022 19:04 | Only good thing about Kromek is that the market thinks they are utterly hopeless, incompetent and worthless. If they can prove they are just mostly hopeless, mostly but not always useless and have an ounce of real value somewhere - the share price might surge briefly… A pivotal year as ST says. I think that’s his final call on Kromek. After the ‘pivotal year’ is over Kromek will be cut loose from their only supporter and shall be drifting with zero hope. | aqc888 | |
23/3/2022 18:29 | As an anecdote- Dragons’ Den seem to respect anyone who puts their life style on line for something they truly believe in - like remortgaging their properties. Any evidence of that here? IMO DYOR. GLA | simithy | |
23/3/2022 17:57 | Notwithstanding not having any scientific retort, are the Directors still paying themselves at top whack while they can? Maybe stretching out the cash flow might buy some time? | simithy | |
23/3/2022 08:38 | There is also a serious disconnect with his shareholders. He should also take a look at these blog boards to see what his shareholders think of him! But then again……& | b00mb0y | |
23/3/2022 07:31 | He needs to own a decent stake in his business he founded or step aside. How can any investor have faith in a business which does not have the belief of the founder and ceo. Step aside or invest Arnab. | aqc888 | |
23/3/2022 07:12 | Arnab, please look at the share price. It is screaming strategic review. There is a serious disconnect between the value of the business and the stock market valuation. You need to stop chasing rainbows | slicethepie | |
22/3/2022 21:33 | How low can this go? | b00mb0y | |
22/3/2022 20:30 | “March deadline may come and go…” “That’s the risk we take” A ridiculous point of view - the risk you’re taking is on the investment in the science. The risk you’re taking should NOT be the risk of the management feeding you complete rubbish repeatedly. With Kromek you’re taking a risk on the science BUT with an extra layer of risk that the management will be fiddling all the facts/making up deadlines/ forgetting targets deadlines promises etc etc etc. How can you assess risk when you’re never given the correct facts. Eg Detector works but can’t give the details of the accreditation etc etc. Eg trials are all great - but can’t tell you any details etc. Its like an insurance company trying assess a risk when they are fed incorrect information. Most would refuse to quote. Most fund managers likewise refuse to invest in Kromek. Simply not a credible company. The proof of that is the FOUNDER & CEO owning a tiny minuscule percentage. | aqc888 | |
22/3/2022 13:48 | Just had to read it... the end of March may well come-and-go, but that was part of the risk we all knew and still know. Meanwhile we didn't ramp it to high heaven and then crash like Icarus! | dougmachin | |
18/3/2022 21:26 | Two weeks till the self imposed deadline expires for sales of the full spectrum biological pathogen detector. They were supposedly in “serious discussions with multiple governments” - according to the CEO. Will anything come of it? Or will the deadline come and go with never another mention by the board. Just like so many other times… The never ending hunt for the end of the Kromek rainbow… | aqc888 | |
17/3/2022 19:39 | The one step forward two steps back scenario just been demonstrated. Hmmm, wonder why I don’t listen to myself? Haha. | b00mb0y | |
16/3/2022 17:16 | Yes. Up it is! But beware of the one step forward two steps back malarkey. | b00mb0y | |
16/3/2022 13:38 | Even KMK's up today! | dougmachin | |
11/3/2022 04:39 | Look at this "AQC" post from late Jan. What changed? Did Basu wear you down like the rest of us? "The Simon Thompson tip will give the share price a good boost tomorrow 5-10% I presume, the print edition will be published on Friday, hopefully cementing tomorrow’s boost. I really wouldn’t rule Kromek out of featuring in the early feb bargain shares edition - which would see further and much bigger gains. 2022 is looking like the year it could all come together. Very limited downside especially at 15p and huge potential gains on x3 fronts in 2022, any one of which could multiply Kromeks share price - nuclear detector sales, biological pathogen detector governmental sales and sale of part of business." | ark87 | |
11/3/2022 04:03 | Simon Thompson Tick Tock getting close to that April deadline. "Firstly, during our results call, chief executive Arnab Basu revealed that he expects first commercial sales by April for Kromek’s bio-security pathogen detectors" | ark87 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions